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Abstract
Chronic kidney disease is common and frequently complicated with hypertension. As a major 
modifiable risk factor for cardiovascular disease in this high risk population, treatment of 
hypertension in chronic kidney disease is of paramount importance. We review the epidemiology 
and pathogenesis of hypertension in chronic kidney disease and then update the latest study results 
for treatment including salt restriction, invasive endovascular procedures, and pharmacologic 
therapy. Recent trials draw into question the efficacy of renal artery stenting or renal denervation 
for hypertension in chronic kidney disease, as well as renin-angiotensin-aldosterone system 
blockade as first line therapy of hypertension in end stage renal disease. Positive trial results 
reemphasize salt restriction and challenge the prevailing prejudice against the use of thiazide-like 
diuretics in advanced chronic kidney disease. Lastly, clinical practice guidelines are trending away 
from recommending tight blood pressure control in chronic kidney disease.
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INTRODUCTION
Chronic kidney disease (CKD) is defined as the presence of kidney damage or abnormal 
kidney function for at least three months duration [1]. CKD is a major public health concern 
on account of both its prevalence and its complications. Based on National Health and 
Nutrition Examination Survey (NHANES) data the prevalence of CKD has been increasing, 
up to more recent estimates of 13.1% of the population in the United States, a proportion 
similar to that of diabetes mellitus [2]. As with diabetes, CKD is increasingly being 
recognized as a cardiovascular risk equivalent [3]. Notably the many adverse sequelae of 
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CKD become more common with advancing stage, and the prevalence of at least moderate 
(stage 3) CKD is estimated at over 8% of the population [2].
EPIDEMIOLOGY
Hypertension is a frequent complication of CKD and when present it is often poorly 
controlled in the CKD population. As a recent example, a cross sectional study of CKD 
patients from the Chronic Renal Insufficiency Cohort (CRIC) study found a prevalence of 
85.7% for hypertension defined as BP ≥ 140/90 or use of an antihypertensive medication 
[4]. Hypertension control rates were higher in the CRIC study compared to previous cohorts 
with 67.1% and 46.1% controlled to a goal BP of < 140/90 or < 130/80 respectively. 
However it should be noted that within the hypertensive CRIC cohort, 58% were on 
treatment with 3 or more antihypertensive medications suggesting that a large proportion of 
the cohort had resistant hypertension.
While the exact prevalence varies depending on whether pre-dialysis BP, post-dialysis BP, 
or interdialytic ambulatory BP is examined, hypertension is also common in patients with 
end stage renal disease (ESRD) on dialysis. A recent cross sectional study of 369 HD 
patients illustrates this point as 82% of subjects had hypertension defined as use of 
antihypertensive drugs or 44 hour interdialytic ambulatory average BP ≥ 135/85, and 
hypertension was adequately controlled in 38% [5].
PATHOPHYSIOLOGY
While comorbid conditions that exacerbate hypertension such as increased arterial stiffness 
[6] and obstructive sleep apnea [7] are common in the CKD population, numerous 
mechanisms more specific to renal disease are proposed to contribute to hypertension. 
Sodium loading has long been clinically recognized as a major and essential contributor to 
hypertension both in those with normal renal function [8] and in those with renal disease [9]. 
As glomerular filtration rate (GFR) declines with progression of CKD, less sodium is 
filtered leading to sodium retention and an expanded extracellular fluid volume. Another 
classically recognized contributor is an inappropriately activated renin-angiotensin-
aldosterone system (RAAS) [10], possibly provoked by renal ischemia in patients with 
renovascular disease.
More recently, sympathetic nervous system overactivity arising from renal efferent nerves 
has gained recognition as a significant contributor to hypertension in CKD as demonstrated 
by the finding of increased muscle sympathetic nerve activity in ESRD patients compared to 
normal controls or to ESRD patients status post bilateral nephrectomy [11]. Another unique 
contributor to sympathetic overactivity is renalase, a novel enzyme secreted by the kidney 
that metabolizes circulating catecholamines and which is deficient in CKD both in animal 
models and in humans [12].
CKD patients have additional causes of vasoconstriction including impaired nitric oxide 
synthesis from circulating inhibitors such as asymmetric dimethyl arginine [13]. Endothelin 
receptor activation contributes to vasoconstriction as elevated levels of endothelin-1 have 
been documented in various stages of CKD [14] and endothelin receptor blockade has 
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shown at least initial success in improving hypertension in humans [15]. More recently, 
phase II studies with endothelin-1 receptor antagonist that is highly selective for the type A 
receptor demonstrate between 35–40% lowering in albuminuria at 12 weeks of treatment 
and reduction in 24h ambulatory blood pressure of 4–6 mmHg over the same period [16].
Lastly, medications can provoke hypertension in the CKD population. While over the 
counter nonsteroidal anti-inflammatory drugs and decongestants can exacerbate 
hypertension, erythropoiesis stimulating agents are commonly prescribed for the anemia of 
CKD and resultant hypertension has been reported in up to 30% of patients [17]. The precise 
mechanism of how erythropoietin causes hypertension is unknown, but current evidence 
suggests that it is independent of hemoglobin level and more likely is mediated via 




Given the central importance of volume overload in the pathogenesis of hypertension in 
kidney disease, restricting sodium intake is an important strategy for treating hypertension in 
CKD. While recent trials have shown low sodium to be efficacious for treating resistant 
hypertension without kidney disease [19] and for reduction of proteinuria and albuminuria 
[20], those studies examining low sodium diet for control of hypertension in CKD have been 
hampered by lack of randomization or blinding or a lack of gold standard BP measurements.
A recent elegantly designed randomized controlled 6 week trial demonstrated the efficacy of 
a low sodium diet in 20 patients with stage 3–4 CKD and elevated office BP [21]. Subjects 
were counseled on low sodium diet and were provided with samples of low sodium foods 
and after a run-in phase they were randomized to receive sodium tablets versus placebo 
before washout and cross over, with a goal sodium intake < 80 mmol per day in the low 
sodium group and 200 mmol per day in the high sodium group. At baseline subjects had an 
average 24 hour ambulatory BP of 151/82 mmHg and the improvement in average 24 hour 
ambulatory BP on the low sodium diet compared to high sodium diet was both statistically 
and clinically significant at 9.7/3.9 mmHg [21]. Both proteinuria and albuminuria were 
significantly improved on the low sodium diet. Importantly, questionnaires, pill counts, and 
24 hour urine collections were used to confirm compliance with sodium content in the diets 
and a steady potassium intake between groups.
Animal studies demonstrate that reducing gut sodium absorption by inhibiting uptake of 
dietary sodium using the drug tenepanor, a non-absorbable inhibitor of the NHE3 transporter 
can reduce BP and protect the kidneys among animals with subtotal nephrectomy [22]. 
Among normal healthy volunteers the drug reduces sodium absorption in a dose-dependent 
manner by about 50 mmol per day without causing diarrhea. Clinical trials in diabetic 
nephropathy are in progress to evaluate the antihypertensive and antiproteinuric effects of 
this drug.
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In the ESRD population, reducing total body sodium content is achieved by reducing the dry 
weight, where a 1 kg average reduction in dry weight has been shown to improve average 44 
hour interdialytic ambulatory BP by 6.6/3.3 mmHg during an 8 week clinical trial, without 
extending the HD time or changing antihypertensive medications [23]. Achieving and 
maintaining an adequately low dry weight is a hands-on and iterative process that requires 
attention to details beyond only the prescribed dry weight [24]. This includes adherence to a 
low sodium diet and minimization of dialysate sodium content, both to reduce interdialytic 
weight gain [25]. Additionally, extending the dialysis time can make ultrafiltration easier to 
tolerate thus facilitating the achievement of an adequate dry weight, while shorter dialysis 
times have recently been shown to be associated both with higher BP and slower 
improvement in BP when dry weight is reduced [26]. Similarly, more frequent HD may also 
facilitate adequate ultrafiltration, and while the Frequent Hemodialysis Network trial didn’t 
find a significant improvement in the trial’s composite primary endpoint, the investigators 
did find significant reductions in weekly average pre-HD SBP and in the number of 
antihypertensive medications needed for the intervention group that dialyzed six times 
weekly [27].
Renal Artery Stenting
Artherosclerotic renal artery stenosis is common in CKD, with prevalence reported at high 
as 40% in patients initiating dialysis [28]. As renal artery stenosis leads to a state of elevated 
RAAS activity, it is attractive to consider angioplasty and stenting of the affected artery to 
relieve the ischemic stimulus promoting renin output. While prior randomized controlled 
trials failed to show significant benefit for angioplasty compared to medical therapy to treat 
hypertension, the subjects in those studies typically had only moderate renal artery stenosis 
and no CKD [29]. In contrast, the recently reported Cardiovascular Outcomes in Renal 
Atherosclerotic Lesions (CORAL) trial recruited 931 subjects both with severe renal artery 
stenosis and with estimated GFR < 60 mL/min/1.73m2 and then randomized them to 
medical therapy versus renal artery stenting plus medical therapy[30]. Over a median follow 
up of 43 months the CORAL trial did not find a benefit to renal artery stenting for the 
primary composite endpoint of cardiovascular and renal events. In a longitudinal analysis 
there was a statistically significant but clinically only modest improvement in SBP of 2.3 
mmHg in the stented group, while the number of antihypertensive medications was no 
different between groups. The CORAL trial findings therefore echo the BP results of two 
other recent large randomized trials of renal artery stenting in CKD that both found no 
benefit for their primary renal outcomes and no improvement in BP as a secondary outcome 
[31;32]. It is likely that the consistent lack of antihypertensive efficacy for renal artery 
stenting in the setting of atherosclerotic renal artery stenosis is due to lesions that are too 
distal and diffuse within the renal arterial tree to be amenable to intervention.
Renal Denervation
Recent uncontrolled and unblinded trials of endovascular radiofrequency ablation of the 
renal nerves showed significant and dramatic BP improvement in patients with resistant 
hypertension, generating considerable enthusiasm for this novel therapy [33]. To address the 
methodological shortcomings of previous trials, the recently reported SYMPLICITY HTN-3 
trial randomized 535 subjects with resistant hypertension but without CKD to either 
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endovascular renal denervation or a sham procedure, and then followed these subjects for 6 
months while their antihypertensive medications were held constant [34]. In contrast to the 
prior unblinded studies, the investigators found no significant improvement in either office 
BP or ambulatory BP in this trial. While these results call into question the efficacy of 
endovascular renal denervation, it remains possible that the negative results of the trial may 
have been due to lack of experience of the operators. More important, unlike angioplasty, 
there is no objective way to measure whether denervation has actually occurred. Short of 
performing cumbersome norepinephrine spillover there are few biomarkers to establish that 
the denervation procedure was effective.
Theoretically, patients with CKD represent a unique population that may benefit from this 
intervention in light of the known over-activity of the sympathetic nervous system in this 
disease. In fact a recent uncontrolled pilot trial of 12 subjects with ESRD and resistant 
hypertension treated with endovascular renal denervation found significant reductions in 
office BP and in the number of antihypertensive medications required [35]. However, the 
divergent findings between the initial open label studies without sham denervation and later 
blinded studies of renal denervation in patients without renal dysfunction require that 
caution be exercised and further blinded trials are needed before renal denervation can be 
deemed effective for treatment of hypertension in CKD.
PHARMACOLOGIC TREATMENT
As patients with substantial CKD and ESRD are commonly excluded from randomized 
controlled trials, there is a paucity of evidence to guide the choice of medications to treat 
hypertension in patients with renal disease. While acknowledging this limitation, the 
recently published clinical practice guidelines from the Eighth Joint National Committee 
(JNC 8) [36] and the Kidney Disease: Improving Global Outcomes (KDIGO) initiative [37] 
both emphasize the use of angiotensin converting enzyme inhibitors (ACEi) and angiotensin 
receptor blocking (ARB) medications in the CKD population based on the results of older 
trials. However, dual use of ACEi and ARB medications is currently contraindicated in light 
of the recently reported results of the Veterans Affairs Nephropathy in Diabetes 
(NEPHRON-D) trial that enrolled 1448 patients with diabetic nephropathy, with or without 
hypertension [38]. Subjects were randomized to losartan plus lisinopril versus losartan plus 
placebo for prevention of a primary composite endpoint of renal events or death and the trial 
was halted early for lack of efficacy as well as for increased adverse events in the dual 
therapy group. Notably, BP was no different between groups.
While it is classically acknowledged that diuretic treatment is frequently necessary for 
hypertension control in CKD, the dogma has been to avoid thiazide-like diuretics in 
advanced CKD with GFR < 30 mL/min/1.73m2 [39]. However, two recent uncontrolled 
trials challenge that paradigm. The first trial enrolled 14 patients with average estimated 
GFR 27 mL/min/1.73m2 and average 24 hour ambulatory SBP 143 on a median of 4 
antihypertensive medications, and after a run-in phase all patients were treated with 
chlorthalidone 25 mg daily with the dose titrated up unless not tolerated [40]. At the end of 
the 12 week intervention the subjects had a significant 10.5 mmHg reduction in 24 hour 
systolic ambulatory BP, and the treatment was generally well tolerated.
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The second trial enrolled 60 CKD patients with average estimated GFR 39 mL/min/1.73m2 
and average office SBP 151 mmHg on 1.8 antihypertensive medications [41]. After a run-in 
phase all patients were started and maintained on chlorthalidone 25 mg daily and at the end 
of the 8 week intervention office SBP was significantly reduced by 20 mmHg. Notably, the 
9 patients with estimated GFR < 30 mL/min/1.73m2 had a similar significant reduction in 
office BP.
In the ESRD population on dialysis, two meta analyses of randomized controlled trials have 
shown nonspecific antihypertensive therapy to be associated with reduced risk of 
cardiovascular events[42;43], but there remains a dearth of clinical trial evidence available 
to guide the choice of medication class when treating hypertension in dialysis patients. The 
Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril (HDPAL) trial 
begins to address that shortcoming. This trial randomized 200 HD patients both with 
hypertension defined as 44 hour interdialytic ambulatory BP ≥ 135/85 and with left 
ventricular hypertrophy to antihypertensive therapy with a regimen based on open label 
atenolol versus lisinopril for reduction in left ventricular hypertrophy as the primary 
endpoint [44]. Over the course of 1 year patients were treated with additional 
antihypertensives and dry weight reduction to maintain home BP ≤ 140/90 checked monthly. 
The trial was halted early for excess serious adverse events in the lisinopril group, and the 
primary endpoint was no different between groups at the time of the study’s halt. 
Interestingly, the subjects in the lisinopril group had a higher home BP and required more 
antihypertensive drugs during the study, despite having more reduction in dry weight, 
suggesting that sympathetic overdrive may be a larger contributor to hypertension in ESRD 
than RAAS excess. Importantly, because there was no placebo group the HDPAL results do 
not necessarily indicate that lisinopril therapy is harmful, only that atenolol is superior in 
comparison.
Also recently reported, the Olmesartan Clinical Trial in Okinawa Patients Under Okinawa 
Dialysis Study (OCTOPUS) investigated the efficacy of ARB therapy for hypertension by 
recruiting 469 HD patients with hypertension defined as pre-HD BP ≥ 140/90 [45]. Subjects 
were randomized to open label treatment with an olmesartan based regimen or to therapy 
excluding ARB or ACEi drugs to achieve pre-HD BP < 140/90 for prevention of a primary 
composite endpoint of death plus cardiovascular events. After a mean follow up of 3.5 years 
the investigators found no difference in the primary outcome or in BP levels between 
groups. Taking the HDPAL and OCTOPUS results into account, we have begun to prescribe 
beta-blockers before ACEi or ARB medications when starting pharmacologic therapy for 
hypertension in our own HD patients.
GOAL BLOOD PRESSURE
A recent retrospective cohort study of over 650,000 veterans with CKD examined the 
relationship between BP and mortality, and with a median follow-up of 5.8 years the 
investigators found an increased risk of death for SBP < 130 mmHg or DBP < 70 mmHg 
[46]. While the findings in this predominantly white and elderly population may not be 
generalizable and causality cannot be determined from an observational study, these 
findings contribute to a trend of reanalyzing both the efficacy and potential harm of 
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previously tight BP goals in CKD. Based on randomized controlled trial data, the JNC 8 no 
longer recommends a BP goal < 130/80 in CKD patients [36] and the recommendations for a 
lower BP goal in the KDIGO guidelines are now heavily qualified [35]. The Systolic Blood 
Pressure Intervention Trial (SPRINT) is ongoing and its results will be informative. In this 
trial over 9,000 hypertensive patients with cardiovascular risk factors including CKD have 
been recruited and randomized to a standard office SBP goal of < 140 mmHg or an intensive 
goal of SBP < 120 mmHg with the intent to prevent the primary endpoint of cardiovascular 
events.
Owing to a lack of clinical trial evidence, goal BP levels in ESRD remain controversial with 
some observational studies finding a decreased risk of mortality associated with high peri-
dialytic BP [47] however when the gold standard of ambulatory BP monitoring is employed, 
a strong and classical relationship emerges between high BP and mortality [48]. Ambulatory 
BP measurement is cumbersome to patients so we favor home BP monitoring as a 
convenient method that is superior to office or dialysis BP in correlating to ambulatory BP 
as well as for predicting prognosis in both HD and predialysis CKD patients [49].
CONCLUSION
While negative or harmful study outcomes can be frustrating, they may still offer valuable 
contributions to the accumulated knowledge in the field and afford providers new 
information on which to build their evidence based practice. Recent results in studies of 
CKD guide us away from routine use of renal artery stenting, renal denervation, dual ACEi 
and ARB therapy, ACEi or ARB medications as first line therapy in HD, and tight BP goals 
in CKD. Further, recent positive results make us question the old paradigm of avoiding 
thiazide-like diuretics in advanced CKD, reemphasize the efficacy of sodium restriction and 
among hemodialysis patients encourage us to use atenolol as first line antihypertensive 
therapy.
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